Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity

Cancer Journal from Scientific American

Volumn 6, Issue SUPPL. 1, 2000, Pages

  Lotze, Michael T ^a,b   Shurin, Michael ^a   Esche, Clemens ^a   Tahara, Hideaki ^a   Storkus, Walter ^a   Kirkwood, John M ^a   Whiteside, Theresa L ^a   Elder, Elaine M ^a   Okada, Hideho ^a   Robbins, Paul ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cytokine gene therapy; Dendritic cells; FLT3 ligand; Interleukin 2; Interleukin 12; Melanoma

Indexed keywords

GLYCOPROTEIN GP 100; HEMOPOIETIC GROWTH FACTOR; HLA ANTIGEN; INTERLEUKIN 12; MONOPHENOL MONOOXYGENASE; RECOMBINANT INTERLEUKIN 2; CANCER VACCINE; FLT3 LIGAND PROTEIN; INTERLEUKIN 2; MEMBRANE PROTEIN; CD40 ANTIGEN; FLT3 LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 4; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; NITRIC OXIDE; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; DENDRITIC CELL; FIBROBLAST; GENE THERAPY; HUMAN; KIDNEY CARCINOMA; MELANOMA; PRIORITY JOURNAL; TUMOR IMMUNITY; IMMUNOLOGY; METABOLISM; NEOPLASM; REVIEW; ANIMAL MODEL; CLINICAL ARTICLE; CLINICAL TRIAL; GENE; IMMUNOTHERAPY; MOUSE; NONHUMAN; T LYMPHOCYTE; TREATMENT OUTCOME;

CANCER VACCINES; DENDRITIC CELLS; FIBROBLASTS; GENE THERAPY; HUMANS; INTERLEUKIN-12; INTERLEUKIN-2; MELANOMA; MEMBRANE PROTEINS; NEOPLASMS;

EID: 0033844006     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lotze MT. Getting to the source: dendritic cells as therapeutic reagents for the treatment of patients with cancer [editorial; comment]. Ann Surg 1997;226:1-5.
2. Wilson CC, Tueting T, Ma D et al. Activation of dendritic cells by surrogate T cell interactions leads to enhanced costimulation, secretion of TH1-associated cytokines, and CTL inducive capacity. Adv Exp Med Biol 1997;417:335-343.
3. Tuting T, Storkus WJ, Lotze MT. Gene-based strategies for the immunotherapy of cancer. J Mol Med 1997;75:478-491.
4. Palucka K, Banchereau J. Linking innate and adaptive immunity [news; comment]. Nature Med 1999;5:868-870.
5. Hagmann M. Elusive interferon alpha producers nailed down [news; comment]. Science 1999;284:1746.
6. Siegal FP, Kadowaki N, Shodell M et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-1837.
7. Vakkila J, Hurme M. Both dendritic cells and monocytes induce autologous and allogeneic T cells receptive to interleukin 2. Scand J Immunol 1990;31:75-83.
8. Zirvogel L, Couderc B, Mayordomo JI et al. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann NY Acad Sci 1996;795:284-293.
9. Nishioka Y, Hirao M, Robbins PD et al. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified ro express interleukin 12. Cancer Res 1999;59:4035-4041.
10. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990;8:253-278.
11. Houssiau FA, Coulie PG, Van Snick J. Distinct roles of IL-1 and IL-6 in human T cell activation. J Immunol 1989;143:2520-2524.
12. Okada M, Kitahara M, Kishimoto S et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141:1543-1549.
13. Takai Y, Wong GG, Clark SC et al. B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes. J Immunol 1988;140:508-512.
14. Uyttenhove C, Coulie PG, Van Snick J. T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 1988;167: 1417-1427.
15. Schwarz MA, Hamilton LD, Tardelli L et al. Stimulation of cytolytic activity by interleukin-10. J Immunother Emphasis Tumor Immunol 1994;16:95-104.
16. Cohen S. IL-10 and IL-3 synergize to cause proliferation of human T cells. Immunology 1995;85:351-356.
17. Kundu N, Beaty TL, Jackson MJ et al. Antimetastatic and antitumor activities of interleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 1996;88:536-541.
18. Wong HL, Wilson DE, Jenson JC et al. Characterization of a factor(s) which synergizes with recombinant interleukin 2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 1988;111:39-54.
19. Nastala CL, Edington HD, McKinney TG et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-1706.
20. Zitvogel L, Tahara H, Robbins PD et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-1403.
21. Tahara H, Zitvogel L, Storkus W et al. Phase I clinical trial of interleukin-12 (IL-12) gene therapy using direct injection of tumors with genetically engineered fibroblasts [abstract 579]. Proc Am Soc Clin Oncol 1996;15:235.
22. Shurin MR, Pandharipande PP, Zorina TD et al. FLT3 ligand induces the generation of functionally active dendritic cells in mice. Cell Immunol 1997;179:174-184.
23. Shurin MR, Esche C, Lotze MT. FET3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev 1998;9:37-48.
24. McKenna HJ, de Vries P, Brasel K et al. Effect of FLT3 ligand on the ex vivo expansion of human CD34+ hematopoietic progenitor cells. Blood 1995;86:3413-3420.
25. Rusten ES, Lyman SD, Veiby OP et al The FET3 ligand is a direct and potent stimulator of the growth of primitive and committed human CD34+ bone marrow. Blood 1996;87:1317-1325.
26. Siens S, Di Nicola MBM, Mortarini R et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol 1995;23:1463-1471.
27. Saraya K, Reid CD. Stem cell factor and the regulation of dendritic cell production from CD34+ progenitors in bone marrow and cord blood. Br J Haematol 1996;93:258-264.
28. Peron JM, Esche C, Subbotin VM et al. FLT3-ligand administration inhibits liver metastases: role of NK cells. J Immunol 1998; 161:6164-6170.
29. Osaki T, Hashimoto W, Gambotto A et al. Potent antitumor effects mediated by local expression of the mature form of the interferon-gamma inducing factor, interleukin-18 (IL-18). Gene Ther 1999;6:808-815.
30. Zhang J, Wenthold RJ Jr, Yu ZX et al. Characterization of the pulmonary lesions induced in rats by human recombinant interleukin-2. Toxicol Pathol 1995;23:653-666.
31. Elder RL, Stolinski LA, Whiteside TL et al. Interleukin-2 treatment causes acute loss of DC precursors and mature DC which rebound with the increase in lymphocytes. J Immunother, in press.
32. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-287.
33. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1995;1: 1297-1302.
34. Turing T, Zorina T, Ma D et al. Development of dendritic cell-based genetic vaccines for cancer. Adv Exp Med Biol 1997;417: 511-518.
35. Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor pepride-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
36. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998;4:328-332.